Targeted regimens mainly focus on critical signaling molecules and cascades driving RCC proliferation, such as the VEGF pathway, which promotes tumor angiogenesis, and the mTOR pathway, which governs pivotal cellular functions. The gene discussed is VEGFA; the disease is renal cell carcinoma.